# Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin

> **NCT01929863** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 16 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** GSK2330672
- **DRUG:** Placebo
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT01929863
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-01
- **Primary completion:** 2013-11-01
- **Final completion:** 2013-11-21
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01929863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01929863, "Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01929863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*